New national and regional bryophyte records, 52

Marchantia paleacea is a new species for the Umbria Region and is rare in central and southern Italy. This record is in a Site of Community Importance (SCI) IT5220017 and a Special Area of Conservation (SAC) of the Natura 2000 EU-wide network due to the presence of the 7220* ‘Petrifying springs with tufa formation (Cratoneurion)’ Annexe I priority habitat. The particular environment, with a gorge and waterfall, created a very special microclimate that allowed the establishment of interesting liverworts and mosses

Hydraulic conductivity of two geosynthetic clay liners permeated with a hyperalkaline solution

GCLs containing powdered Na-bentonite treated with different dosages of a proprietary additive intended to reduce the impacts of chemical interactions were permeated with three solutions: a hyperalkaline solution (1 M NaOH and 1.3 mM CsCl) having similar pH to aluminum refining leachate, a 1.3 mM CsCl solution (no NaOH). and DI water. For a given permeant solution, the hydraulic conductivity of both GCLs was similar. Thus, the higher additive dosage had no measureable impact on hydraulic conductivity. Hydraulic conductivity of both GCLs decreased by a factor of approximately 1.5-1.8 during permeation with CsCl in response to osmotic swelling induced by the low ionic strength of the CsCl solution entering the pore space. In contrast, permeation with the NaOH-CsCl solution caused the hydraulic conductivity of both GCLs to increase modestly (<50 times the hydraulic conductivity to DI water), and then level out (or decrease slightly) as a result of reduced osmotic swelling in the interlayer combined with dissolution of the mineral. For the tests conducted with CsCl solution, nearly all of the Cs was adsorbed by the bentonite. In contrast, Cs broke through readily when the NaOH-CsCl solution was used as the permeant solution. Permeation with the NaOH-CsCl solution also increased the sodicity of the bentonite by replacing bound K, Ca, and Mg on the mineral surface. (C) 2009 Elsevier Ltd. All rights reserved

Long-term dental anomalies after pediatric cancer treatment in children [Kanser tedavisi gören çocuklarda uzun süre sonra görülen diş anomalileri]

PubMed ID: 30322830Objective: The aim of this study is to determine the frequency of dental anomalies (DAs) (microdontia, hypodontia, hyperdontia, enamel defect, root malformation) in pediatric cancer patients at the ages <5 years and between 5 and 7 years, and understand their relationship with the received therapy. Materials and Methods: Pediatric patients who were diagnosed with cancer and treated before the age of 7 years were investigated in a case-control design. The study included 93 pediatric patients whose ages at diagnosis were between 9 months and 7 years and whose treatments were completed before 5-8 years. Group A consisted of patients in the age range of 9 months to 4 years and Group B consisted of patients in the age range of 5-7 years. Seventy-two siblings with compatible dental age ranges were included in the control group. For both groups, intraoral examinations were performed and panoramic radiographs were taken. Results: Among the 93 pediatric patients, the mean age was 9.54±1.25 (range: 8-13 years) and 48 (51.6%) patients were male. The most common diagnosis was hematologic malignancy with a rate of 65.5%. At least one DA was detected in 7 (9.7%) individuals of the control group and in 78 (83.9%) of the patient group. While the patients in the study group had all kinds of DAs, those in the control group had only enamel defects. The rates of microdontia (p=0.077) and hypodontia (p=0.058) were detected to be significantly higher in Group A than in Group B. Root malformation was more common in patients receiving chemotherapy and radiotherapy than in those receiving only chemotherapy (p=0.006). Conclusion: In this study it was found that the pediatric patients who received cancer treatment before the age of 7 years constituted a high-risk group for DAs. The frequencies of microdontia and hypodontia were increased even more when the patient was treated for cancer before 5 years of age. © 2019 by Turkish Society of Hematology